Noveome Biotherapeutics receives rare paediatric disease designation and orphan drug designation for the treatment of necrotising enterocolitis in neonates

Noveome Biotherapeutics

24 May 2022 - Noveome Biotherapeutics today announced that the U.S. FDA has granted rare paediatric disease designation and orphan drug designation to the company’s lead product ST266 for the treatment of necrotising enterocolitis.

ST266 is a cell free sterile biologic solution containing hundreds of proteins and other factors at physiologic levels.

Read Noveome Biotherapeutics press release

Michael Wonder

Posted by:

Michael Wonder